| Literature DB >> 18534912 |
Pablo Villoslada1, Beatriz Moreno, Ignacio Melero, Jose L Pablos, Gianvito Martino, Antonio Uccelli, Xavier Montalban, Jesus Avila, Serge Rivest, Laia Acarin, Stanley Appel, Samia J Khoury, Patrick McGeer, Isidro Ferrer, Mario Delgado, Jose Obeso, Michal Schwartz.
Abstract
The burden of neurological diseases in western societies has accentuated the need to develop effective therapies to stop the progression of chronic neurological diseases. Recent discoveries regarding the role of the immune system in brain damage coupled with the development of new technologies to manipulate the immune response make immunotherapies an attractive possibility to treat neurological diseases. The wide repertoire of immune responses and the possibility to engineer such responses, as well as their capacity to promote tissue repair, indicates that immunotherapy might offer benefits in the treatment of neurological diseases, similar to the benefits that are being associated with the treatment of cancer and autoimmune diseases. However, before applying such strategies to patients it is necessary to better understand the pathologies to be targeted, as well as how individual subjects may respond to immunotherapies, either in isolation or in combination. Due to the powerful effects of the immune system, one priority is to avoid tissue damage due to the activity of the immune system, particularly considering that the nervous system does not tolerate even the smallest amount of tissue damage.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18534912 DOI： 10.1016/j.clim.2008.04.003
Source DB: PubMed Journal: Clin Immunol ISSN： 1521-6616 Impact factor: 3.969